WHC is still in active development. Read this to understand our approach.
depiction of VTTONGPRPXSUTJ-UHFFFAOYSA-N.svg
psychonaut

Bufotenin

Check on psychonaut

isomerdesign

Bufotenin

Check on isomerdesign

drugmap

bufotenine

Check on drugmap

wiki

Bufotenin

Check on wiki

Data

InChI: InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3

Synonyms: DB-012579,DMT,5-OH,Oprea1_475603,GTPL144,DSSTox_RID_83089,3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol #,5-Hydroxy-N,N-dimethyltryptamine,{3-[(beta-Dimethylamino)ethyl]-5-hydroxyindole},DEA No. 7433,1,5-benzoxazepin-4(5H)-one, 2,3-dihydro-8-methoxy-2,2,5,6-tetramethyl-,Cohoba,Indol-5-ol, 3-[2-(dimethylamino)ethyl],1H-Indol-5-ol, 3-[2-(dimethylamino)ethyl]-,487-93-4,3-[2-(Dimethylamino)ethyl]indol-5-ol,CHEBI:3210,PDSP1_000007,DB01445,5-HO-DMT,3-(2-dimethylaminoethyl)-1H-indol-5-ol,3-[(.beta.-Dimethylamino)ethyl]-5-hydroxyindole,INDOL-5-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-,CHEMBL416526,Tox21_112890,5-Hydroxy-N, N-dimethyltryptamine,Tryptamine, N,N-dimethyl-5-hydroxy,5-OH-DMT,3-(.beta.-Dimethylaminoethyl)-5-hydroxyindole,N,N-Dimethyl-5-hydroxytryptamine,3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol,Bufotenine 1.0 mg/ml in Acetonitrile,Mappine, N,N-dimethyl-5-HT,SCHEMBL518028,Dimethylserotonin,NSC 89593,BUFOTENINE [MI],Bufotenine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material,3-[2-(Dimethylamino)ethyl]-5-indolol,1H-Indol-5-ol, 3-(2-(dimethylamino)ethyl)-,AKOS005445162,BDBM50024206,0A31347TZK,{3-[(2-Dimethylamino)ethyl]-5-indolol},NSC-89593,N,N-Dimethyl-5-HT,DTXSID0048894,Indol-5-ol, {3-[2-(dimethylamino)ethyl]-},CAS-487-93-4,3-[(2-Dimethylamino)ethyl]-5-indolol,3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol,Cinobufotenine, 5-OH-DMT, dimethylserotonin,BUFOTENINE [MART.],STK368137,FT-0623282,DM5-HT,3-(2-Dimethylaminoethyl)-5-indolol,L001128,ZINC1070,3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol (ACD/Name 4.0),WLN: T56 BMJ D2N1&1 GQ,N,N-Dimethylserotonin,3-(2-Dimethylaminoethyl)-1H-indol-5-ol,5-22-12-00026 (Beilstein Handbook Reference),PDSP2_000007,3-(2-Dimethylaminoethyl)indol-5-ol,Q408915,NCGC00247724-01,Indol-5-ol, 3-[2-(dimethylamino)ethyl]-,3-[2-(Dimethylamino)ethyl]-Indol-5-ol,DSSTox_CID_28820,1H-Indol-5-ol, {3-[2-(dimethylamino)ethyl]-},DSSTox_GSID_48894, N,N-dimethylserotonin,Mappin,BRN 0160628,8-methoxy-2,2,5,6-tetramethyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one,UNII-0A31347TZK,N, N-Dimethylserotonin,Mapine,3-(beta-Dimethylaminoethyl)-5-hydroxyindole,Bufotenine,Bufotenin,NSC89593,3-[.beta.-(Dimethylamino)ethyl]-5-hydroxyindole,EINECS 207-667-9,C08299,3-[beta-(Dimethylamino)ethyl]-5-hydroxyindole


Estimated data

Solubility: -1.523 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 91.6% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.